Leibovici L, Gransden W R, Eykyn S J, Konsiberger H, Drucker M, Pitlik S D, Phillips I
Department of Medicine B, Beilinson Medical Centre, Petah Tiqva, Israel.
J Intern Med. 1993 Jul;234(1):83-9. doi: 10.1111/j.1365-2796.1993.tb00709.x.
To define risk factors associated with bacteraemia caused by Staphylococcus aureus or coagulase-negative staphylococci; and to use them to define patients in need of empiric anti-staphylococcal antibiotic treatment.
Derivation set: observational, prospective study; validation set: retrospective analysis of a prospectively collected database.
Derivation set: Beilinson Medical Centre, Petah Tiqva, Israel--a 900-bed university hospital. Validation set: St Thomas's Hospital, London, UK--an 800-bed teaching hospital.
All episodes of bacteraemia detected at Beilinson Medical Centre between March 1988 and September 1990 (derivation set, n = 1410), and at St Thomas's Hospital during 1987-1990 (validation set, n = 1040).
None.
Percentage of staphylococcal bacteraemia in groups of patients defined by the models.
The following factors were associated with Staphylococcus aureus bacteraemia: focus of infection (whether high or low risk), haemodialysis, intravenous drug abuse and infection acquired in the orthopaedic ward. A logistic model was used to divide the derivation set into three groups with percentages of Staphylococcus aureus bacteraemia of 1.8%, 13.2% and 33.7% (P < 0.0001); and the validation group 2.5%, 18.2% and 53.2% (P < 0.0001). Factors associated with coagulase-negative staphylococcal bacteraemia were: central or peripheral intravenous catheter as the focus of infection, a preterm neonate, the presence of a central intravenous catheter, low temperature, and a low white blood cell count. A second model including those factors was used to divide the derivation set into three groups with percentages of coagulase-negative staphylococcal bacteraemia of 1.9%, 22.8%, and 43% (P < 0.0001). In the validation set, the percentages were 2.9%, 22.4% and 31.0% (P < 0.001).
The present study defines groups at high risk for staphylococcal bloodstream infection, in which empiric treatment should include an anti-staphylococcal drug.
确定与金黄色葡萄球菌或凝固酶阴性葡萄球菌引起的菌血症相关的危险因素;并利用这些因素确定需要经验性抗葡萄球菌抗生素治疗的患者。
推导集:观察性前瞻性研究;验证集:对前瞻性收集的数据库进行回顾性分析。
推导集:以色列佩塔提克瓦的贝林森医疗中心——一家拥有900张床位的大学医院。验证集:英国伦敦的圣托马斯医院——一家拥有800张床位的教学医院。
1988年3月至1990年9月在贝林森医疗中心检测到的所有菌血症病例(推导集,n = 1410),以及1987 - 1990年期间在圣托马斯医院的病例(验证集,n = 1040)。
无。
模型定义的患者组中葡萄球菌菌血症的百分比。
以下因素与金黄色葡萄球菌菌血症相关:感染部位(高风险或低风险)、血液透析、静脉药物滥用以及在骨科病房获得的感染。使用逻辑模型将推导集分为三组,金黄色葡萄球菌菌血症的百分比分别为1.8%、13.2%和33.7%(P < 0.0001);验证组分别为2.5%、18.2%和53.2%(P < 0.0001)。与凝固酶阴性葡萄球菌菌血症相关的因素有:中心或外周静脉导管作为感染部位、早产儿、存在中心静脉导管、低温以及白细胞计数低。使用包含这些因素的第二个模型将推导集分为三组,凝固酶阴性葡萄球菌菌血症的百分比分别为1.9%、22.8%和43%(P < 0.0001)。在验证集中,百分比分别为2.9%、22.4%和31.0%(P < 0.001)。
本研究确定了葡萄球菌血流感染的高危人群,其中经验性治疗应包括抗葡萄球菌药物。